Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:CDIO NASDAQ:ENLV NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.81+1.5%$0.94$0.57▼$3.85$26.50M0.27274,381 shs30,133 shsCDIOCardio Diagnostics$3.99+3.1%$3.94$3.22▼$53.10$7.04M2.9418,768 shs18,784 shsENLVEnlivex Therapeutics$1.05-0.5%$1.22$0.81▼$2.10$24.72M0.83275,681 shs70,526 shsRLYBRallybio$0.59-1.8%$0.54$0.22▼$1.24$24.60M-1.1296,491 shs107,062 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%+2.97%-12.17%-28.04%-74.13%CDIOCardio Diagnostics0.00%+5.14%+9.62%+7.55%-51.64%ENLVEnlivex Therapeutics0.00%-2.34%+1.46%-4.13%-32.58%RLYBRallybio0.00%-2.03%-0.91%+92.04%-46.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.81+1.5%$0.94$0.57▼$3.85$26.50M0.27274,381 shs30,133 shsCDIOCardio Diagnostics$3.99+3.1%$3.94$3.22▼$53.10$7.04M2.9418,768 shs18,784 shsENLVEnlivex Therapeutics$1.05-0.5%$1.22$0.81▼$2.10$24.72M0.83275,681 shs70,526 shsRLYBRallybio$0.59-1.8%$0.54$0.22▼$1.24$24.60M-1.1296,491 shs107,062 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%+2.97%-12.17%-28.04%-74.13%CDIOCardio Diagnostics0.00%+5.14%+9.62%+7.55%-51.64%ENLVEnlivex Therapeutics0.00%-2.34%+1.46%-4.13%-32.58%RLYBRallybio0.00%-2.03%-0.91%+92.04%-46.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 3.00Buy$3.30306.20% UpsideCDIOCardio Diagnostics 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.00Buy$10.00856.94% UpsideRLYBRallybio 2.00Hold$5.00749.47% UpsideCurrent Analyst Ratings BreakdownLatest CDIO, AKTX, ENLV, and RLYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.009/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.609/2/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/18/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/29/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/22/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ACDIOCardio Diagnostics$19.51K360.61N/AN/A$7.10 per share0.56ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/ARLYBRallybio$640K38.43N/AN/A$1.49 per share0.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%9/25/2025 (Estimated)CDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-30,465.10%-72.78%-66.17%11/12/2025 (Estimated)ENLVEnlivex Therapeutics-$15.01M-$0.58N/AN/AN/AN/A-58.31%-50.32%12/5/2025 (Estimated)RLYBRallybio-$57.78M-$0.94N/AN/AN/A-5,473.33%-71.66%-65.06%11/6/2025 (Estimated)Latest CDIO, AKTX, ENLV, and RLYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025AKTXAkari Therapeutics-$0.09N/AN/AN/AN/AN/A8/14/2025Q2 2025CDIOCardio Diagnostics-$1.80-$0.97+$0.83-$0.97$0.08 million$0.01 million8/7/2025Q2 2025RLYBRallybio-$0.2450-$0.22+$0.0250-$0.22N/A$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19CDIOCardio DiagnosticsN/A23.5223.52ENLVEnlivex TherapeuticsN/A6.416.41RLYBRallybioN/A9.989.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%CDIOCardio Diagnostics8.06%ENLVEnlivex Therapeutics1.02%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%CDIOCardio Diagnostics13.30%ENLVEnlivex Therapeutics12.28%RLYBRallybio8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableCDIOCardio Diagnostics11.76 million1.53 millionNot OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableRLYBRallybio4041.79 million38.15 millionNot OptionableCDIO, AKTX, ENLV, and RLYB HeadlinesRecent News About These CompaniesRallybio receives $12.5M equity milestone payment from Recursion PharmaceuticalsSeptember 3, 2025 | msn.comRallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 ProgramSeptember 3, 2025 | finance.yahoo.comRallybio Granted Extension for Nasdaq ComplianceAugust 29, 2025 | tipranks.comTD Cowen Reaffirms Their Buy Rating on Rallybio (RLYB)August 12, 2025 | theglobeandmail.comRallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024)August 9, 2025 | finance.yahoo.comRallybio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 8, 2025 | finance.yahoo.comEvercore ISI Remains a Hold on Rallybio (RLYB)July 16, 2025 | theglobeandmail.comRXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ... - NasdaqJuly 11, 2025 | nasdaq.comRallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - MorningstarJuly 9, 2025 | morningstar.comMHere's Why Shares in Recursion Pharmaceuticals Surged TodayJuly 8, 2025 | finance.yahoo.comRallybio Sells Interest in REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | finance.yahoo.comRecursion to buy Rallybio’s ownership in jointly developed bone disorder drugJuly 8, 2025 | msn.comRallybio Sells REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | tipranks.comRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyJune 13, 2025 | finance.yahoo.comRallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlookMay 24, 2025 | investing.comRallybio shareholders elect directors, ratify auditorMay 18, 2025 | uk.investing.comRallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comJones Trading Downgrades Rallybio (RLYB)April 15, 2025 | msn.comRallybio downgraded to Hold from Buy at JonesResearchApril 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDIO, AKTX, ENLV, and RLYB Company DescriptionsAkari Therapeutics NASDAQ:AKTX$0.81 +0.01 (+1.52%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.79 -0.02 (-2.76%) As of 09/19/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cardio Diagnostics NASDAQ:CDIO$3.99 +0.12 (+3.10%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.98 -0.01 (-0.13%) As of 09/19/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Enlivex Therapeutics NASDAQ:ENLV$1.04 -0.01 (-0.48%) Closing price 09/19/2025 03:55 PM EasternExtended Trading$1.04 0.00 (0.00%) As of 09/19/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Rallybio NASDAQ:RLYB$0.59 -0.01 (-1.77%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.60 +0.02 (+2.79%) As of 09/19/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
